Medetomidine

Dr. Reddy's announces the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market

Retrieved on: 
Friday, September 25, 2020

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection, approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection, approved by the U.S. Food and Drug Administration (USFDA).
  • Our ability to adequately supply Dexmedetomidine is important for patients as it is on the FDAs Drug Shortage list.
  • The Precedex in 0.9% Sodium Chloride Injection brand and generic market had U.S. sales of approximately $210 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
  • Dr. Reddys Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is available in 200 mcg/50 mL (4 mcg/mL) and 400 mcg/100 mL (4 mcg/mL) in 50 mL and 100 mL clear glass vials, respectively.

Slayback Pharma announces approval and immediate launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in 200 mcg/ 50 mL and 400 mcg/ 100 mL (4 mcg/mL) vials, generic equivalent of Precedex™ 4 mcg/ mL

Retrieved on: 
Tuesday, December 10, 2019

PRINCETON, N.J., Dec. 10, 2019 /PRNewswire/ --Slayback Pharma LLC announced today the final approval and launch in the United States of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection.

Key Points: 
  • PRINCETON, N.J., Dec. 10, 2019 /PRNewswire/ --Slayback Pharma LLC announced today the final approval and launch in the United States of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection.
  • Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is available in 200 mcg/50 mL and 400 mcg/ 100 mL (4 mcg/mL) vials, and can be ordered through your wholesaler/distributor.
  • Due to the known pharmacological effects of dexmedetomidine hydrochloride in 0.9% sodium chloride injection, patients should be continuously monitored while receiving dexmedetomidine hydrochloride in 0.9% sodium chloride injection.
  • Some patients receiving dexmedetomidine hydrochloride in 0.9% sodium chloride injection have been observed to be arousable and alert when stimulated.

Fresenius Kabi Introduces Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection

Retrieved on: 
Thursday, June 20, 2019
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190620005112/en/
    Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride now available from Fresenius Kabi.
  • (Photo: Business Wire)
    Fresenius Kabi Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is available in 20 mL vials, as well as 50 mL and 100 mL bottles.
  • The introduction of these Dexmedetomidine presentations complement Fresenius Kabis previously available Dexmedetomidine HCl injection 2 mL single dose vials.
  • Please click on this link ( https://tinyurl.com/y48s4udz ) for the full prescribing information for Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection.